Pacira Biosciences, Stock Shares Outstanding
| PCRX Stock | USD 22.07 0.98 4.65% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Pacira BioSciences,'s long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Pacira BioSciences, Company Shares Outstanding Analysis
Pacira BioSciences,'s Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Pacira BioSciences, Shares Outstanding | 46.3 M |
Most of Pacira BioSciences,'s fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pacira BioSciences, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Pacira BioSciences, has 46.3 M of shares currently outstending. This is 74.35% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The shares outstanding for all United States stocks is 91.9% higher than that of the company.
Pacira Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pacira BioSciences,'s direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pacira BioSciences, could also be used in its relative valuation, which is a method of valuing Pacira BioSciences, by comparing valuation metrics of similar companies.Pacira BioSciences, is currently under evaluation in shares outstanding category among its peers.
Pacira Fundamentals
| Return On Equity | -0.12 | ||||
| Return On Asset | 0.0356 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 1.12 B | ||||
| Shares Outstanding | 46.3 M | ||||
| Shares Owned By Insiders | 1.78 % | ||||
| Shares Owned By Institutions | 98.22 % | ||||
| Number Of Shares Shorted | 5.46 M | ||||
| Price To Earning | 14.34 X | ||||
| Price To Book | 1.22 X | ||||
| Price To Sales | 1.45 X | ||||
| Revenue | 700.97 M | ||||
| Gross Profit | 463.44 M | ||||
| EBITDA | 32.25 M | ||||
| Net Income | (99.56 M) | ||||
| Cash And Equivalents | 316.39 M | ||||
| Cash Per Share | 6.90 X | ||||
| Total Debt | 638.85 M | ||||
| Debt To Equity | 1.10 % | ||||
| Current Ratio | 3.95 X | ||||
| Book Value Per Share | 17.25 X | ||||
| Cash Flow From Operations | 189.39 M | ||||
| Short Ratio | 10.63 X | ||||
| Earnings Per Share | (2.24) X | ||||
| Price To Earnings To Growth | (3.83) X | ||||
| Target Price | 30.8 | ||||
| Number Of Employees | 788 | ||||
| Beta | 0.49 | ||||
| Market Capitalization | 1.02 B | ||||
| Total Asset | 1.55 B | ||||
| Retained Earnings | (206.36 M) | ||||
| Working Capital | 435.21 M | ||||
| Current Asset | 252.58 M | ||||
| Current Liabilities | 149.79 M | ||||
| Net Asset | 1.55 B |
About Pacira BioSciences, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pacira BioSciences,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacira BioSciences, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacira BioSciences, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.